TOP

We collaborate with the AHSN Network to spread innovation and best practice across the country through our shared programmes and national NHS initiatives.

Please contact us if you would like to find out about or gain support on any of our programmes

 

AHSN Programmes

The Innovation Agency and the AHSN Network are rolling out programmes of innovation on behalf of our national NHS commissioners. From April 2020 three programmes have been selected for national adoption and spread which have evidence of impact. These are:

Early Intervention Eating Disorders > Improving Diagnosis of ADHD > Lipid management and FH >

We still are offering support for our national programmes of 2018-2020. Please get in touch for more information. Our past programmes are:

 

National Patient Safety Improvement Programmes

The Innovation Agency leads the Patient Safety Collaborative for the North West Coast and delivers the National Patient Safety Improvement Programme in the region.

Read more >>>

Workstreams:

Managing Deterioration > Medicines > Maternity and Neonatal > Mental Health > Adopt and Spread >

 

Cardiovascular (CVD) and respiratory disease management and improvement

Cardiovascular disease (CVD) and respiratory disease are Innovation Agency priorities for innovation and improvement from 2020-2023. Find out more >>>

We will be focusing on four key areas:

Atrial fibrillation > Respiratory > Lipid management > Long‑term conditions >

 

Innovation Exchange

Funded by the government’s Office for Life Sciences and along with our fellow AHSNs we support the regional ‘import and export’ of healthcare innovation through our national Innovation Exchange programme. Find out more >>> 

The Innovation Agency also provides the regional Innovation Exchange platform for the North West Coast. It is an online forum for colleagues across the healthcare sector to share innovative solutions, projects and products to improve patient care.

 

Rapid Uptake Products (RUPs)

The Rapid Uptake Products (RUP) programme has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date. The 2020/21 programme builds on the successes of the 2019/20 RUPs programme, with themes selected via an open, staged, selection process. Find out more >>> [AHSN Network website]

Selected products are:

Placental growth factor (PIGF) based tests to rule out preeclampsia HeartFlow FFRCT to diagnose coronary heart disease PCSK9 inhibitors Lipid Management Measuring nitric oxide (FeNO) in asthma Biologics for treating severe asthma Tamoxifen for prevention of breast cancer

 

MedTech Funding Mandate

The Innovation Agency and our fellow AHSNs are offering support to technologies that will be supported by the NHS MedTech Funding Mandate 2021/22 policy, some of which are also Rapid Uptake Products. Find out more >>>

Supported innovations are:

Placental growth factor (PIGF) based tests to rule out preeclampsia HeartFlow FFRCT to diagnose coronary heart disease SecurAcath for securing percutaneous catheters gammaCore non‑invasive vagus nerve stimulation

 

 

Find out about other national spread and adoption programmes and collaborations >>>

All the latest from the Innovation Agency...